On ubiquitin ligases and cancer

被引:7
作者
Beckmann, JS [1 ]
Maurer, F
Delorenzi, M
Falquet, L
机构
[1] CHU Vaudois, Univ Hosp, Serv Med Genet, CH-1011 Lausanne, Switzerland
[2] Swiss Canc Res Inst, Natl Ctr Competence Res, Mol Oncol Program, Epalinges, Switzerland
[3] Swiss Inst Bioinformat, Epalinges, Switzerland
关键词
E3 ubiquitin ligase; deubiquitinase; ubiquitylation; protein kinase; signal transduction; oncogene; cancer;
D O I
10.1002/humu.20175
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Protein kinase genes account for almost 10% of all currently known cancer genes, highlighting the role of signal transduction in oncogenesis. A reexamination of the literature and available databases shows that E3 ubiquitin ligases are also key mediators of tumorigenesis. Altogether kinase and E3 genes represent more than 15% of the known cancer genes, underlining the importance of phosphorylation and ubiquitylation signaling pathways in cancer formation. Considering the recent literature reporting correlations between alterations in ubiquitylation processes and oncogenesis, this percentage is likely to increase even further in the future. Finally, E3 genes could serve as baits for the identification of additional cancer genes (e.g. their interacting partners). In contrast, deubiquitinases, like phosphatases, are not overrepresented among cancer genes. The same holds for E1 and E2 genes. Thus, kinase and E3 genes represent primary targets as cancer susceptibility genes for mutation screening and for the design of novel therapies. (c) 2005 Wiley-Liss, Inc.
引用
收藏
页码:507 / 512
页数:6
相关论文
共 34 条
[1]  
Apweiler R, 2004, NUCLEIC ACIDS RES, V32, pD115, DOI [10.1093/nar/gkw1099, 10.1093/nar/gkh131]
[2]   Scores of RINGs but No PHDs in Ubiquitin Signaling [J].
Aravind, L. ;
Iyer, L. M. ;
Koonin, E. V. .
CELL CYCLE, 2003, 2 (02) :123-126
[3]   The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis [J].
Barry, RE ;
Krek, W .
TRENDS IN MOLECULAR MEDICINE, 2004, 10 (09) :466-472
[4]   Ensembl 2004 [J].
Birney, E ;
Andrews, D ;
Bevan, P ;
Caccamo, M ;
Cameron, G ;
Chen, Y ;
Clarke, L ;
Coates, G ;
Cox, T ;
Cuff, J ;
Curwen, V ;
Cutts, T ;
Down, T ;
Durbin, R ;
Eyras, E ;
Fernandez-Suarez, XM ;
Gane, P ;
Gibbins, B ;
Gilbert, J ;
Hammond, M ;
Hotz, H ;
Iyer, V ;
Kahari, A ;
Jekosch, K ;
Kasprzyk, A ;
Keefe, D ;
Keenan, S ;
Lehvaslaiho, H ;
McVicker, G ;
Melsopp, C ;
Meidl, P ;
Mongin, E ;
Pettett, R ;
Potter, S ;
Proctor, G ;
Rae, M ;
Searle, S ;
Slater, G ;
Smedley, D ;
Smith, J ;
Spooner, W ;
Stabenau, A ;
Stalker, J ;
Storey, R ;
Ureta-Vidal, A ;
Woodwark, C ;
Clamp, M ;
Hubbard, T .
NUCLEIC ACIDS RESEARCH, 2004, 32 :D468-D470
[5]   Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors [J].
Blagosklonny, MV .
ONCOGENE, 2001, 20 (03) :395-398
[6]   A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans [J].
Bond, GL ;
Hu, WW ;
Bond, EE ;
Robins, H ;
Lutzker, SG ;
Arva, NC ;
Bargonetti, J ;
Bartel, F ;
Taubert, H ;
Wuerl, P ;
Onel, K ;
Yip, L ;
Hwang, SJ ;
Strong, LC ;
Lozano, G ;
Levine, AJ .
CELL, 2004, 119 (05) :591-602
[7]   The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications [J].
Burger, AM ;
Seth, AK .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (15) :2217-2229
[8]   A central role for the ring finger protein RNF11 in ubiquitin-mediated proteolysis via interactions with E2s and E3s [J].
Connor, MK ;
Seth, A .
ONCOGENE, 2004, 23 (11) :2089-2095
[9]   PHD domains and E3 ubiquitin ligases: viruses make the connection [J].
Coscoy, L ;
Ganem, D .
TRENDS IN CELL BIOLOGY, 2003, 13 (01) :7-12
[10]   The ubiquitin ligase COP1 is a critical negative regulator of p53 [J].
Dornan, D ;
Wertz, I ;
Shimizu, H ;
Arnott, D ;
Frantz, GD ;
Dowd, P ;
O' Rourke, K ;
Koeppen, H ;
Dixit, VM .
NATURE, 2004, 429 (6987) :86-92